Logo image of ABEO

ABEONA THERAPEUTICS INC (ABEO) Stock Fundamental Analysis

NASDAQ:ABEO - US00289Y2063 - Common Stock

6.85 USD
+0.02 (+0.29%)
Last: 9/2/2025, 8:00:00 PM
6.85 USD
0 (0%)
After Hours: 9/2/2025, 8:00:00 PM
Fundamental Rating

3

ABEO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 542 industry peers in the Biotechnology industry. ABEO may be in some trouble as it scores bad on both profitability and health. ABEO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ABEO had negative earnings in the past year.
ABEO had a negative operating cash flow in the past year.
ABEO had negative earnings in each of the past 5 years.
ABEO had a negative operating cash flow in each of the past 5 years.
ABEO Yearly Net Income VS EBIT VS OCF VS FCFABEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

ABEO's Return On Assets of 23.25% is amongst the best of the industry. ABEO outperforms 97.23% of its industry peers.
The Return On Equity of ABEO (34.99%) is better than 97.97% of its industry peers.
Industry RankSector Rank
ROA 23.25%
ROE 34.99%
ROIC N/A
ROA(3y)-70.3%
ROA(5y)-74.66%
ROE(3y)-224.16%
ROE(5y)-183.97%
ROIC(3y)N/A
ROIC(5y)N/A
ABEO Yearly ROA, ROE, ROICABEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

ABEO's Profit Margin of 14310.50% is amongst the best of the industry. ABEO outperforms 99.82% of its industry peers.
The Operating Margin and Gross Margin are not available for ABEO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 14310.5%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABEO Yearly Profit, Operating, Gross MarginsABEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

ABEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ABEO has more shares outstanding
Compared to 5 years ago, ABEO has more shares outstanding
Compared to 1 year ago, ABEO has a worse debt to assets ratio.
ABEO Yearly Shares OutstandingABEO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ABEO Yearly Total Debt VS Total AssetsABEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

ABEO has an Altman-Z score of -1.56. This is a bad value and indicates that ABEO is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ABEO (-1.56) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.09 indicates that ABEO is not too dependend on debt financing.
ABEO has a Debt to Equity ratio of 0.09. This is in the lower half of the industry: ABEO underperforms 63.28% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z -1.56
ROIC/WACCN/A
WACC9.86%
ABEO Yearly LT Debt VS Equity VS FCFABEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

ABEO has a Current Ratio of 6.73. This indicates that ABEO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 6.73, ABEO is in the better half of the industry, outperforming 67.16% of the companies in the same industry.
A Quick Ratio of 6.65 indicates that ABEO has no problem at all paying its short term obligations.
ABEO has a better Quick ratio (6.65) than 67.16% of its industry peers.
Industry RankSector Rank
Current Ratio 6.73
Quick Ratio 6.65
ABEO Yearly Current Assets VS Current LiabilitesABEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 30.63% over the past year.
Looking at the last year, ABEO shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)30.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-378.95%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ABEO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.58% yearly.
Based on estimates for the next years, ABEO will show a very strong growth in Revenue. The Revenue will grow by 420.09% on average per year.
EPS Next Y94.37%
EPS Next 2Y43.74%
EPS Next 3Y38.62%
EPS Next 5Y27.58%
Revenue Next Year26442.2%
Revenue Next 2Y3315.94%
Revenue Next 3Y1164.88%
Revenue Next 5Y420.09%

3.3 Evolution

ABEO Yearly Revenue VS EstimatesABEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
ABEO Yearly EPS VS EstimatesABEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ABEO. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 59.50, the valuation of ABEO can be described as expensive.
88.93% of the companies in the same industry are more expensive than ABEO, based on the Price/Forward Earnings ratio.
ABEO is valuated expensively when we compare the Price/Forward Earnings ratio to 22.52, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 59.5
ABEO Price Earnings VS Forward Price EarningsABEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABEO Per share dataABEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

ABEO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ABEO's earnings are expected to grow with 38.62% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.74%
EPS Next 3Y38.62%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ABEO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABEONA THERAPEUTICS INC

NASDAQ:ABEO (9/2/2025, 8:00:00 PM)

After market: 6.85 0 (0%)

6.85

+0.02 (+0.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-12 2025-11-12
Inst Owners63.09%
Inst Owner Change18.28%
Ins Owners5.68%
Ins Owner Change-5.47%
Market Cap351.27M
Analysts86.67
Price Target20.91 (205.26%)
Short Float %18.25%
Short Ratio10.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.37%
Min EPS beat(2)-36.14%
Max EPS beat(2)35.41%
EPS beat(4)2
Avg EPS beat(4)1.9%
Min EPS beat(4)-52.88%
Max EPS beat(4)61.23%
EPS beat(8)4
Avg EPS beat(8)-1.59%
EPS beat(12)7
Avg EPS beat(12)23.36%
EPS beat(16)9
Avg EPS beat(16)14.81%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.87%
PT rev (3m)3.99%
EPS NQ rev (1m)-309.64%
EPS NQ rev (3m)13.43%
EPS NY rev (1m)76.92%
EPS NY rev (3m)32.24%
Revenue NQ rev (1m)-16.29%
Revenue NQ rev (3m)45.61%
Revenue NY rev (1m)5.71%
Revenue NY rev (3m)19.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 59.5
P/S 878.17
P/FCF N/A
P/OCF N/A
P/B 2.15
P/tB 2.15
EV/EBITDA N/A
EPS(TTM)-1.54
EYN/A
EPS(NY)0.12
Fwd EY1.68%
FCF(TTM)-1.39
FCFYN/A
OCF(TTM)-1.29
OCFYN/A
SpS0.01
BVpS3.19
TBVpS3.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 23.25%
ROE 34.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 14310.5%
GM N/A
FCFM N/A
ROA(3y)-70.3%
ROA(5y)-74.66%
ROE(3y)-224.16%
ROE(5y)-183.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 172.41%
Cap/Sales 1328%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.73
Quick Ratio 6.65
Altman-Z -1.56
F-Score5
WACC9.86%
ROIC/WACCN/A
Cap/Depr(3y)32.9%
Cap/Depr(5y)51.12%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-378.95%
EPS Next Y94.37%
EPS Next 2Y43.74%
EPS Next 3Y38.62%
EPS Next 5Y27.58%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year26442.2%
Revenue Next 2Y3315.94%
Revenue Next 3Y1164.88%
Revenue Next 5Y420.09%
EBIT growth 1Y-31.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-65.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-54.12%
OCF growth 3YN/A
OCF growth 5YN/A